Adaptive Biotechnologies Corporation · NASDAQ (us_market)
Healthcare · Diagnostics & Research · United States
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-27$19.23 RISE2026-05-18$12.71 PEAK2026-05-28$15.19 121d | -33.9% 111d | Missed | Missed | — | — | +19.5% 10d | Missed |
DROP2025-11-24$20.46 RISE2026-03-27$12.41 PEAK2026-05-28$15.19 185d | -39.3% 123d | Missed | Missed | — | — | +22.4% 62d | Missed |
DROP2025-10-20$17.83 RISE2025-11-17$13.71 PEAK2025-11-24$20.46 35d | -23.1% 28d | Missed | Missed | — | — | +49.2% 7d | Missed |
DROP2025-06-26$12.16 RISE2025-07-31$10.24 PEAK2025-10-20$17.83 116d | -15.8% 35d | Missed | Missed | — | — | +74.1% 81d | Missed |
DROP2025-03-24$8.66 RISE2025-04-21$6.83 PEAK2025-06-26$12.16 94d | -21.1% 28d | Missed | Missed | — | — | +78.0% 66d | Missed |
DROP2025-02-13$8.52 RISE2025-03-10$6.67 PEAK2025-05-05$10.03 81d | -21.7% 25d | Missed | Missed | — | — | +50.4% 56d | Missed |
DROP2024-11-11$6.49 RISE2024-11-21$4.37 PEAK2025-02-13$8.52 94d | -32.7% 10d | Missed | Missed | — | — | +95.0% 84d | Missed |
DROP2024-08-15$4.93 RISE2024-09-25$4.00 PEAK2024-12-16$6.78 123d | -18.9% 41d | Missed | Missed | — | — | +69.5% 82d | Missed |
DROP2024-02-27$4.27 RISE2024-06-18$3.08 PEAK2024-08-15$4.93 170d | -27.9% 112d | Missed | Missed | — | — | +60.1% 58d | Missed |
DROP2023-12-28$5.33 RISE2024-04-18$2.34 PEAK2024-07-16$4.45 201d | -56.2% 112d | Missed | Missed | — | — | +90.6% 89d | Missed |
DROP2023-09-27$5.64 RISE2024-02-05$3.46 PEAK2024-02-27$4.27 153d | -38.7% 131d | Missed | Missed | — | — | +23.4% 22d | Missed |
DROP2023-07-31$8.44 RISE2023-11-13$3.46 PEAK2023-12-28$5.33 150d | -59.1% 105d | Missed | Missed | — | — | +54.3% 45d | Missed |
DROP2023-03-03$9.08 RISE2023-07-07$6.04 PEAK2023-07-31$8.44 150d | -33.5% 126d | Missed | Missed | — | — | +39.7% 24d | Missed |
DROP2023-01-17$10.11 RISE2023-05-18$6.19 PEAK2023-06-13$8.78 147d | -38.8% 121d | Missed | Missed | — | — | +41.8% 26d | Missed |
DROP2022-08-25$11.20 RISE2022-12-28$6.91 PEAK2023-01-17$10.11 145d | -38.3% 125d | Missed | Missed | — | — | +46.3% 20d | Missed |
1–15 / 29 1 / 2 | |||||||
Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and lowers the price target from $21 to $18.
Adaptive Biotechnologies (ADPT) has attracted fresh attention after reporting first quarter 2026 results, along with higher full year revenue guidance for its Minimal Residual Disease business, supported by growing clonoSEQ adoption and broader payor coverage. See our latest analysis for Adaptive Biotechnologies. Despite the raised MRD guidance and solid first quarter update, Adaptive Biotechnologies' share price has been volatile, with a 7.98% 1 month share price gain but a year to date...
2026-05-08. The following slide deck was published by Adaptive Biotechnologies Corporation in conjunction with their 2026 Q1 earnings call.
JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and lowers the price target from $21 to $19.
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $19 to $21.
Guggenheim analyst Subbu Nambi reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $21 price target.
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
Adaptive Biotechnologies beat Q1 2026 estimates with $70.9M revenue, driven by 53% MRD growth. Stock rose 6% after hours as guidance was raised to $260-270M.
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (NASDAQ:ADPT) reported first-quarter 2026 results that executives said showed “accelerating momentum” in measurable residual disease (MRD) testing, alongside continued operational efficiency gains and a higher full-year MRD revenue outlook. MRD growth drives revenue as comp
Adaptive Biotechnologies (NASDAQ:ADPT) reported first-quarter 2026 results that executives said showed “accelerating momentum” in measurable residual disease (MRD) testing, alongside continued operational efficiency gains and a higher full-year MRD revenue outlook. MRD growth drives revenue as comp
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDTCompany ParticipantsKarina Calzadilla - Vice President of Investor...
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter Financial Results. [Operator Instructions] Please be advised
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +16.13% and +14.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +16.13% and +14.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. “We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performa
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ADPT | +6.17% | -6.02% | -6.71% | +59.14% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.20% | -0.30% | -3.27% | +46.45% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Viking | long/short | 29.99M | $416.31M | 1.16% | Unchanged | 2026-03-31 |
| Wellington | fundamental | 3.86M | $53.54M | 0.01% | Added+78.1% | 2026-03-31 |
| StateStreet | passive | 3.23M | $44.79M | 0.00% | Added+1.4% | 2026-03-31 |
| ARKK | disruptive | 2.09M | $29.05M | 0.23% | Trimmed-2.2% | 2026-03-31 |
| DEShaw | quant | 1.97M | $27.28M | 0.02% | Added+3.3% | 2026-03-31 |
| Citadel | multi-strat | 1.02M | $14.18M | 0.02% | Added+403.2% | 2026-03-31 |
| FidelityFMR | fundamental | 567.0K | $7.87M | 0.00% | Added+46.9% | 2026-03-31 |
| RenTech | quant | 239.8K | $3.33M | 0.01% | New | 2026-03-31 |
| TwoSigma | quant | 118.2K | $1.64M | 0.00% | New | 2026-03-31 |
| Bridgewater | macro | 89.7K | $1.25M | 0.01% | Trimmed-66.2% | 2026-03-31 |
| TRowePrice | fundamental | 1.57M | $21.74K | 0.00% | Trimmed-64.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -0.14 | — | — |
| 2026-05-05 | -0.16 | -0.13 | +20.18% |
| 2026-02-05 | -0.18 | -0.09 | +50.78% |
| 2025-11-05 | -0.14 | 0.06 | +143.30% |
| 2025-08-05 | -0.24 | -0.17 | +28.57% |
| 2025-05-01 | -0.31 | -0.20 | +35.48% |
| 2025-02-11 | -0.24 | -0.23 | +5.17% |
| 2024-11-07 | -0.27 | -0.22 | +19.84% |
| 2024-08-01 | -0.33 | -0.29 | +12.02% |
| 2024-05-07 | -0.34 | -0.32 | +6.15% |
| 2024-02-14 | -0.33 | -0.30 | +6.99% |
| 2023-11-09 | -0.34 | -0.35 | -4.45% |
| 2023-08-02 | -0.35 | -0.33 | +4.48% |
| 2023-05-03 | -0.37 | -0.40 | -9.16% |
| 2023-02-14 | -0.35 | -0.28 | +19.71% |
| 2022-11-03 | -0.38 | -0.32 | +14.74% |